Truqap’s positive clinical data comes after it failed a late-stage study in metastatic triple-negative breast cancer. It ...

After a recent failed showing in a breast cancer subgroup raised doubts around AstraZeneca’s Truqap, the first-in-class AKT ...

The results of the phase 3 CAPItello-281 study showed that Truqap (capivasertib) improved radiographic progression-free ...

11月25日，阿斯利康宣布其AKT抑制剂Capivasertib在治疗新发转移性激素敏感性前列腺癌（mHSPC）的III期CAPItello-281研究成功。继Capivasertib乳腺癌适应症获批上市后，此次研究进一步证实了AKT抑制剂的临床价值 ...

The AKT price has surged by almost 30% as the Binance Futures listing boosts trading volume. Bullish momentum is eyeing $4.55 and above.

AI coins TFUEL, ZIG, and AKT see bullish momentum. TFUEL nears $500M cap, ZIG eyes ATH, and AKT approaches $1B in market ...

British drug maker AstraZeneca Plc (AZN.L, AZN) announced Monday positive high-level results from CAPItello-281 Phase III trial of ...

Natural deodorants can be hit or miss, but AKT's unique balm formula is wickedly good and keeps you dry for 24 hours.

BAN price soared 80% while AKT price rose around 25% after Binance Futures launched BANUSDT and AKTUSDT with 75x leverage ...

The Solana ATH is near, AKT is shooting up the charts, and Lunex Network’s DeFi facilities are luring investors by the thousands.

Akash Network (AKT) is surging with a 50% weekly gain, and technical indicators suggest the price could break $6.85, setting ...

Comedian (BAN) surged 80%, and Akash Network (AKT) gained 25% following Binance Futures announcement of USDⓈ-Margined ...